
Please try another search
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is based in Atlanta, Georgia.
Name | Age | Since | Title |
---|---|---|---|
Amit D. Munshi | 57 | 2024 | Independent Chairman |
Dennis N. Berman | 74 | 2020 | Independent Director |
Robert A. Hauser | - | - | Member of Scientific Advisory Board |
Valina L. Dawson | - | - | Member of Scientific Advisory Board |
Roy Lester Freeman | 72 | 2020 | Independent Director |
Ted M. Dawson | - | - | Member of Scientific Advisory Board |
Pankaj Jay Pasricha | - | - | Member of Scientific Advisory Board |
Roberto Francesco Bellini | 45 | 2024 | Independent Director |
David Canner | 37 | 2024 | Independent Director |
Jeffrey H. Kordower | - | - | Member of Scientific Advisory Board |
Kenneth L. Marek | - | - | Member of Scientific Advisory Board |
Mark T. Iwicki | 59 | 2025 | CEO & Director |
Arvind Kush | 41 | 2024 | Independent Director |
Vincent E. Aurentz | 57 | 2025 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review